Kymera Therapeutics, Inc. (NASDAQ:KYMR – Get Free Report) major shareholder Venture Fund X. L.P. Atlas sold 115,090 shares of the company’s stock in a transaction on Wednesday, March 13th. The stock was sold at an average price of $42.23, for a total value of $4,860,250.70. Following the completion of the sale, the insider now owns 4,676,075 shares of the company’s stock, valued at $197,470,647.25. The transaction was disclosed in a filing with the SEC, which is available through this link. Large shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.
Kymera Therapeutics Stock Down 6.6 %
KYMR stock opened at $39.51 on Friday. The stock has a market capitalization of $2.41 billion, a PE ratio of -15.68 and a beta of 2.30. Kymera Therapeutics, Inc. has a 52 week low of $9.60 and a 52 week high of $45.31. The firm has a 50 day moving average of $35.46 and a 200 day moving average of $24.31.
Kymera Therapeutics (NASDAQ:KYMR – Get Free Report) last posted its quarterly earnings results on Thursday, February 22nd. The company reported ($0.25) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.44) by $0.19. The business had revenue of $47.90 million during the quarter, compared to analysts’ expectations of $41.94 million. Kymera Therapeutics had a negative net margin of 187.00% and a negative return on equity of 34.83%. The business’s quarterly revenue was up 197.5% on a year-over-year basis. During the same quarter last year, the company posted ($0.60) earnings per share. On average, equities research analysts expect that Kymera Therapeutics, Inc. will post -3.21 earnings per share for the current year.
Institutional Trading of Kymera Therapeutics
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Price T Rowe Associates Inc. MD increased its holdings in shares of Kymera Therapeutics by 5.5% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 5,335,712 shares of the company’s stock valued at $135,848,000 after purchasing an additional 278,287 shares during the period. BVF Inc. IL boosted its position in Kymera Therapeutics by 8.9% in the fourth quarter. BVF Inc. IL now owns 5,161,801 shares of the company’s stock valued at $131,419,000 after buying an additional 422,797 shares during the last quarter. Vanguard Group Inc. increased its holdings in Kymera Therapeutics by 1.8% in the 4th quarter. Vanguard Group Inc. now owns 3,997,564 shares of the company’s stock worth $101,778,000 after buying an additional 72,351 shares during the period. State Street Corp raised its position in Kymera Therapeutics by 67.8% during the 2nd quarter. State Street Corp now owns 3,514,438 shares of the company’s stock worth $69,199,000 after buying an additional 1,419,877 shares during the last quarter. Finally, BlackRock Inc. raised its position in Kymera Therapeutics by 0.6% during the 1st quarter. BlackRock Inc. now owns 3,419,084 shares of the company’s stock worth $144,698,000 after buying an additional 21,544 shares during the last quarter.
Analyst Ratings Changes
A number of equities analysts have recently weighed in on the company. Wolfe Research assumed coverage on Kymera Therapeutics in a research note on Thursday, February 15th. They issued a “peer perform” rating for the company. JPMorgan Chase & Co. boosted their price target on shares of Kymera Therapeutics from $34.00 to $47.00 and gave the stock an “overweight” rating in a research note on Friday, February 23rd. Wells Fargo & Company lowered Kymera Therapeutics from an “overweight” rating to an “equal weight” rating and set a $26.00 price objective for the company. in a research report on Tuesday, December 19th. Truist Financial boosted their target price on Kymera Therapeutics from $41.00 to $54.00 and gave the stock a “buy” rating in a research report on Friday, March 1st. Finally, Stifel Nicolaus lifted their price objective on Kymera Therapeutics from $35.00 to $55.00 and gave the stock a “buy” rating in a research note on Friday, February 23rd. Six equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $39.89.
Read Our Latest Stock Report on Kymera Therapeutics
Kymera Therapeutics Company Profile
Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.
See Also
Receive News & Ratings for Kymera Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Kymera Therapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.
